{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:20:07Z","timestamp":1791566407238,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10072-024-07460-5","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T03:09:15Z","timestamp":1713755355000},"page":"4229-4241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efgartigimod as a novel FcRn inhibitor for autoimmune disease"],"prefix":"10.1007","volume":"45","author":[{"given":"Yun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-7459","authenticated-orcid":false,"given":"Fan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"7460_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/trf.16341","volume":"61","author":"SL Wyckoff","year":"2021","unstructured":"Wyckoff SL, Hudson KE (2021) Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias. Transfusion 61:1350\u20131354","journal-title":"Transfusion"},{"key":"7460_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","volume":"8","author":"RJ Ludwig","year":"2017","unstructured":"Ludwig RJ, Vanhoorelbeke K, Leypoldt F et al (2017) Mechanisms of autoantibody-induced pathology. Front Immunol 8:603","journal-title":"Front Immunol"},{"key":"7460_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","volume":"61","author":"JL Barnas","year":"2019","unstructured":"Barnas JL, Looney RJ, Anolik JH (2019) B cell targeted therapies in autoimmune disease. Curr Opin Immunol 61:92\u201399","journal-title":"Curr Opin Immunol"},{"key":"7460_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/BOR.0000000000000825","volume":"33","author":"AL Stefanski","year":"2021","unstructured":"Stefanski AL, D\u00f6rner T (2021) Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. Curr Opin Rheumatol 33:592\u2013597","journal-title":"Curr Opin Rheumatol"},{"key":"7460_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3389\/fimmu.2019.01375","volume":"10","author":"R Pollmann","year":"2019","unstructured":"Pollmann R, Walter E, Schmidt T et al (2019) Identification of autoreactive B cell subpopulations in peripheral blood of autoimmune patients with pemphigus vulgaris. Front Immunol 10:1375","journal-title":"Front Immunol"},{"key":"7460_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","volume":"55","author":"M Hale","year":"2018","unstructured":"Hale M, Rawlings DJ, Jackson SW (2018) The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. Curr Opin Immunol 55:81\u201388","journal-title":"Curr Opin Immunol"},{"key":"7460_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.tips.2018.08.004","volume":"39","author":"J Bayry","year":"2018","unstructured":"Bayry J, Kaveri SV (2018) Kill \u2018em all: efgartigimod immunotherapy for autoimmune diseases. Trends Pharmacol Sci 39:919\u2013922","journal-title":"Trends Pharmacol Sci"},{"key":"7460_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540","journal-title":"Front Immunol"},{"key":"7460_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0000000000007605","volume":"92","author":"AC Guidon","year":"2019","unstructured":"Guidon AC, Juel VC (2019) Efgartigimod: a novel antibody depletion therapy in myasthenia gravis. Neurology 92:1079\u20131080","journal-title":"Neurology"},{"key":"7460_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C et al (2020) Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol 146:479-491.e475","journal-title":"J Allergy Clin Immunol"},{"key":"7460_CR11","doi-asserted-by":"crossref","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K (2022) Current treatment of myasthenia gravis. J Clin Med 11","DOI":"10.3390\/jcm11061597"},{"key":"7460_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725","journal-title":"Nat Rev Immunol"},{"key":"7460_CR13","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2019","unstructured":"Gable KL, Guptill JT (2019) Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol 10:3052","journal-title":"Front Immunol"},{"key":"7460_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82:865\u2013887","journal-title":"Drugs"},{"key":"7460_CR15","doi-asserted-by":"crossref","unstructured":"Dos Santos JBR, Gomes RM, da Silva MRR (2022) Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience. Expert Rev Clin Immunol 1\u201310","DOI":"10.1080\/1744666X.2022.2106972"},{"key":"7460_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first Approval. Drugs 82:341\u2013348","journal-title":"Drugs"},{"key":"7460_CR17","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128:4372\u20134386","journal-title":"J Clin Invest"},{"key":"7460_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","volume":"317","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Plomp JJ, van Es IE et al (2019) Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol 317:133\u2013143","journal-title":"Exp Neurol"},{"key":"7460_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536","journal-title":"Lancet Neurol"},{"key":"7460_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776","journal-title":"Front Immunol"},{"key":"7460_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30","journal-title":"Nat Rev Dis Primers"},{"key":"7460_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"7460_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"},{"key":"7460_CR24","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473\u20131494","journal-title":"J Neurol"},{"key":"7460_CR25","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92:e2661\u2013e2673","journal-title":"Neurology"},{"key":"7460_CR26","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood-2016-03-708388","volume":"128","author":"S Cantoni","year":"2016","unstructured":"Cantoni S, Carpenedo M, Nichelatti M et al (2016) Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia. Blood 128:2183\u20132185","journal-title":"Blood"},{"key":"7460_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1055\/s-0032-1305780","volume":"38","author":"R Stasi","year":"2012","unstructured":"Stasi R (2012) Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 38:454\u2013462","journal-title":"Semin Thromb Hemost"},{"key":"7460_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","volume":"146","author":"D Nugent","year":"2009","unstructured":"Nugent D, McMillan R, Nichol JL, Slichter SJ (2009) Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production. Br J Haematol 146:585\u2013596","journal-title":"Br J Haematol"},{"key":"7460_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, S\u00e1nchez-Gonz\u00e1lez B, Rejt\u0151 L et al (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95:178\u2013187","journal-title":"Am J Hematol"},{"key":"7460_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"E Schmidt","year":"2019","unstructured":"Schmidt E, Kasperkiewicz M, Joly P (2019) Pemphigus Lancet 394:882\u2013894","journal-title":"Pemphigus Lancet"},{"key":"7460_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Cs\u00f6rg\u0151 Z, De Simone C et al (2022) Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 186:429\u2013439","journal-title":"Br J Dermatol"},{"key":"7460_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","volume":"19","author":"C Briani","year":"2022","unstructured":"Briani C, Visentin A (2022) Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies. Neurotherapeutics 19:874\u2013884","journal-title":"Neurotherapeutics"},{"key":"7460_CR33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jca.22055","volume":"38","author":"M Yunce","year":"2023","unstructured":"Yunce M, Katyal N, Monis GF, Muppidi S (2023) Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications. J Clin Apheresis 38:632\u2013640","journal-title":"J Clin Apheresis"},{"key":"7460_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s13311-022-01188-w","volume":"19","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC (2022) Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurotherapeutics 19:832\u2013847","journal-title":"Neurotherapeutics"},{"key":"7460_CR35","doi-asserted-by":"crossref","unstructured":"Dade M, Berzero G, Izquierdo C et al (2020) Neurological syndromes associated with anti-GAD antibodies. Int J Molec Sci 21","DOI":"10.3390\/ijms21103701"},{"key":"7460_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","volume":"271","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Alonge P, Rini N et al (2024) Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol 271:254\u2013262","journal-title":"J Neurol"},{"key":"7460_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H et al (2022) Therapeutic effects of batoclimab in chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther 11:815\u2013834","journal-title":"Neurol Ther"},{"key":"7460_CR38","doi-asserted-by":"crossref","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S et al (2017) The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 9","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"7460_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG et al (2019) M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther 105:1031\u20131039","journal-title":"Clin Pharmacol Ther"},{"key":"7460_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V (2023) Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy 15:553\u2013563","journal-title":"Immunotherapy"},{"key":"7460_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs 37:467\u2013473","journal-title":"CNS Drugs"},{"key":"7460_CR42","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","volume":"41","author":"LJ Jara","year":"2022","unstructured":"Jara LJ, Vera-Lastra O, Mahroum N, Pineda C, Shoenfeld Y (2022) Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand? Clin Rheumatol 41:1603\u20131609","journal-title":"Clin Rheumatol"},{"key":"7460_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/1040841X.2019.1614904","volume":"45","author":"HM Hussein","year":"2019","unstructured":"Hussein HM, Rahal EA (2019) The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol 45:394\u2013412","journal-title":"Crit Rev Microbiol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07460-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07460-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:35:36Z","timestamp":1723026936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07460-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7460"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07460-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a drug review article and therefore does not involve medical ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}